Neumora Therapeutics (NMRA) Current Leases (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Current Leases of $291000.0 for Q1 2026, down 68.98% year-over-year from $938000.0 in Q1 2025, and up 2.46% quarter-over-quarter from $284000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Current Leases (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $291000.0 for Q1 2026.
- In Q1 2026, Current Leases fell 68.98% year-over-year to $291000.0; the TTM figure through Mar 2026 stood at $291000.0 (down 68.98% YoY), while the FY2025 annual figure was $284000.0, down 84.67% from the prior year.
- Current Leases for Q1 2026 stood at $291000.0, up from $284000.0 in the prior quarter.
- The five-year high for Current Leases was $3.6 million in Q2 2024, with the low at $171000.0 in Q2 2025.
- The 5-year median for Current Leases is $2.3 million (2024), against an average of $2.0 million.
- The sharpest annual moves came in 2023 and 2025: Current Leases increased 0.24% in 2023, then tumbled 95.26% in 2025.
- Neumora Therapeutics' Current Leases stood at $3.4 million in 2022, then climbed by 0.24% to $3.4 million in 2023, then plunged by 45.15% to $1.9 million in 2024, then plunged by 84.67% to $284000.0 in 2025, then grew by 2.46% to $291000.0 in 2026.
- Business Quant data shows NMRA's Current Leases at $291000.0 in Q1 2026, $284000.0 in Q4 2025, and $256000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 291,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 291,000.00 |
| Dec 31, 2025 | 284,000.00 |
| Sep 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Mar 31, 2025 | 938,000.00 |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 2.75 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.49 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Sep 30, 2023 | 3.40 Mn |
| Dec 31, 2022 | 3.37 Mn |